Market news

FDA establishes Investigational New Animal Drug (INAD) File No. 14145, advancing the Company's companion-animal oncology program and marking first milestone under Lupvindol collaboration

New corporate identity and ticker reflect the Company’s transformation into a diversified cannabinoid-based health sciences platformFORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker symbol “EDVA” effective at market open at 9:30 a.m. Eastern Time on Monday, A

The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take holdFORT LAUDERDALE, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided an update on the Company’s ongoing strategic transformation toward Endovia Health Sciences. For the six months ended June 30, 2026, the Co

New corporate identity reflects Company's strategic evolution into a diversified cannabinoid health sciences platformFORT LAUDERDALE, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the "Company") today announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026. At that time, the Company will also adopt a new ticker symbol of “EDVA” and launch EndoviaSciences.com in connection with the rebranding. Th

Splash Beverage Group (SBEV) on Friday filed a prospectus covering the potential resale of up to 5 m

Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management Splash retains ownership of resulting data, intellectual property and commercialization rights FORT LAUDERDALE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has entered into a strategic development and collaboration agreement with Lupvindol Biosciences Ltd. to advance CannEpil® as a po

Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development platformFORT LAUDERDALE, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash" or the "Company") today announced that it has expanded its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second regulated pharmaceutical development platform alongside the Company's existing human pharmac

Detailed price information for Splash Beverage Group Inc (SBEV-A) from The Globe and Mail including charting and trades.

FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash," "Splash Beverage" or the "Company") today announced two significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE American compliance plan. The Company has successfully negotiated settlements with multiple legacy creditors representing approximately $3.3 million of accounts payable and accrued liabilities for aggregate c

Detailed price information for Splash Beverage Group Inc (SBEV-A) from The Globe and Mail including charting and trades.

Tipranks Press Release.

FORT LAUDERDALE, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash," "Splash Beverage" or the "Company") today announced that NYSE American has accepted the Company's plan to regain compliance with the Exchange's continued listing standards and has granted the Company a compliance period through January 29, 2027. The Exchange's determination follows the Company's submission of its compliance plan on May 29, 2026. The acceptance of the Company's co

Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT) (LSE: RGT) for CannEpil®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.

The company secured an exclusive global licensing agreement for CannEpil.

FORT LAUDERDALE, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX/LSE: RGT) for CannEpil®, a proprietary, cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy (DRE) in multiple European countries. CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been made available in multiple inte